Honestly, if you took a nap during Friday’s market session, you missed one of the most violent biotech breakouts we've seen in years. IBRX stock price today sits at $5.52, after a staggering 39.75% gain in a single day.
This isn't just some "meme stock" pump. We’re looking at a company, ImmunityBio, that basically just proved its flagship cancer drug, Anktiva, is a financial and clinical powerhouse.
What happened to the IBRX stock price today?
The numbers are frankly a bit wild. ImmunityBio closed Friday at its new 52-week high of $5.52. At one point in the afternoon, it actually touched $5.58. Think about that—just a few weeks ago, this was a $2 stock.
Volume was the real story here. Over 182 million shares changed hands. That is more than 1,200% higher than the usual daily average. When that much money moves into a stock at once, it’s not just retail traders on Reddit; it’s institutional conviction.
The 700% revenue explosion
The primary catalyst? ImmunityBio dropped a bombshell regarding their 2025 preliminary financials. Net product revenue for Anktiva hit approximately $113 million, which is a 700% jump compared to the previous year.
Sales are accelerating fast. The fourth quarter of 2025 alone brought in $38.3 million. That’s a 20% increase over the third quarter. It shows that doctors are actually prescribing this stuff for bladder cancer, and the market is finally realizing that the commercial rollout isn’t just hype—it’s reality.
Why the IBRX stock price today is catching everyone off guard
Most people were waiting for "one big thing," but ImmunityBio gave them six. Within just one week, the company secured approval for Anktiva in Saudi Arabia, moved closer to EU marketing approval, and released data showing their drug helps treat lung cancer too.
Clinical wins you can't ignore
Beyond the money, the science is holding up. Dr. Patrick Soon-Shiong, the billionaire behind the company, recently highlighted results from the QUILT-106 trial. In a small group of patients with Waldenström lymphoma—a rare blood cancer—their CAR-NK therapy showed 100% disease control.
Two of those patients have been in complete remission for 7 and 15 months. And they didn't even need chemotherapy or hospital stays. They did it as outpatients. That’s a potential "holy grail" for oncology.
The bladder cancer roadmap
Investors are also laser-focused on the QUILT-2.005 trial for first-line bladder cancer. It’s 85% enrolled right now. Management expects to finish enrollment by Q2 2026 and file for FDA approval by the end of this year. If that gets approved, the addressable market for IBRX explodes.
Is IBRX still undervalued at $5.52?
It sounds crazy to call a stock "cheap" after it doubles in a month, but some analysts think $5.52 is just the floor.
- Analyst Price Targets: The average target is currently sitting around $10.40, with some aggressive estimates reaching as high as $25.20.
- The DCF Math: A Discounted Cash Flow (DCF) analysis from Simply Wall St recently pegged the intrinsic value of ImmunityBio at $18.94.
- The Risk Factor: You've gotta remember this is still a biotech. They are still burning cash and aren't "profitable" in the traditional sense yet. Any delay in the FDA filing for the new bladder cancer indication could cause a sharp pullback.
What most people get wrong about ImmunityBio
A lot of bears focus on the "short float," which is still high at over 32%. They think the stock is only up because of a short squeeze. While the shorts are definitely feeling the heat, a squeeze doesn't happen without a fundamental reason to buy.
👉 See also: 660 mil won to usd: Why This Specific Number Matters Right Now
The 700% revenue growth is that reason. This is transitioning from a "science experiment" to a "commercial company." That is a massive valuation shift that often leaves skeptics behind.
Actionable insights for the week ahead
If you're looking at the IBRX stock price today and wondering what to do, keep an eye on these specific levels and dates:
- Watch the $5.00 support: If the stock pulls back, it needs to stay above $5.00 to keep the bullish momentum alive.
- Monitor the RSI: On many charts, IBRX is looking "overbought" in the short term. A few days of sideways movement or a slight dip wouldn't be surprising after a 40% run.
- The Q2 Deadline: The next major "hard" catalyst is the completion of enrollment for the QUILT-2.005 trial in the spring.
- Cash Reserves: With roughly $242 million in cash and a growing revenue stream, the "bankruptcy" risk that people talked about in 2024 has largely evaporated.
ImmunityBio is no longer just a "story" stock. It’s a revenue-generating machine with a pipeline that could redefine how we treat several different types of cancer. Whether it hits $10 this year or $20 next year, the volatility is part of the ride.